According to recent market research on the Ichroma AMH Test Kit Market, the global demand for point-of-care Anti-Müllerian Hormone (AMH) testing is expanding rapidly due to rising global infertility rates, increasing maternal age, and growing awareness surrounding reproductive health.

Key Drivers

• Delayed Childbearing: Increasing numbers of couples are choosing to conceive later in life, driving the need for routine ovarian reserve assessments.

• Point-of-Care Adoption: Decentralized testing with quick turnarounds (such as the ~12-minute processing time for point-of-care fluorescence immunoassays) is replacing slow reference laboratory workflows.

• Fertility Clinic Expansion: A worldwide surge in IVF centers and reproductive healthcare clinics is boosting system placement rates.

Strategic Market Positioning

The market is characterized by strong competition among microfluidic and immunoassay system manufacturers. Point-of-care options continue to gain market share over traditional microplate Readers due to reduced foot-print requirements and minimal operator training barriers.